The oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib is superior to standard EGFR-TKIs including gefitinib and erlotinib as a first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), according to a recent study.
Ethnicity, insurance status, and other factors are associated with overall survival (OS) in patients with non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer (IASLC) 18TH Annual World Conference on Lung Cancer (October 15-18, 2017; Yokohama, Japan).
Long-term data from a recent trial suggest that continuation of treatment with first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) beyond EGFR-positive non-small cell lung cancer (NSCLC) progression does not improve overall survival (OS).
Adjuvant treatment with the targeted therapy gefitinib (Iressa, AstraZeneca) significantly improved disease-free survival (DFS) over standard of care after surgery for patients with non–small cell lung cancer (NSCLC), according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).
Selecting patients with cyclooxygenase-2 (COX-2) expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical Oncology (published online May 10, 2017; doi:10.1200/JCO.2016.71.3743).
Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with crizotinib may experience increased progression-free survival (PFS) with a decrease in a type of circulating tumor cells, according to research published in Cancer Research (May 2017;77:2222).
Patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) live significantly longer without disease progression when treated with a new drug compared with those treated with crizotinib.